NCT03628339View on ClinicalTrials.gov

Effect of Tepotinib on PK of CYP3A Substrate Midazolam

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 20, 2018

Primary Completion Date

October 25, 2018

Study Completion Date

October 30, 2018

Conditions
Healthy
Interventions
DRUG

Midazolam

Participant received single oral dose of 7.5 mg midazolam tablet on Day 1 of treatment period 1 and Day 11 in treatment period 2.

DRUG

Tepotinib

Participants received single oral dose of 500 mg tepotinib film-coated tablet from Day 1 to 11 in treatment period 2.

Trial Locations (1)

89231

Nuvisan GmbH, Neu-Ulm

All Listed Sponsors
lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT03628339 - Effect of Tepotinib on PK of CYP3A Substrate Midazolam | Biotech Hunter | Biotech Hunter